Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Liabilities: 2019-2024

Historic Total Liabilities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $49.8 million.

  • 4D Molecular Therapeutics' Total Liabilities rose 7.67% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 7.67%. This contributed to the annual value of $49.8 million for FY2024, which is 55.26% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Total Liabilities of $49.8 million as of FY2024, which was up 55.26% from $32.1 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Total Liabilities registered a high of $49.8 million during FY2024, and its lowest value of $30.5 million during FY2022.
  • Its 3-year average for Total Liabilities is $37.4 million, with a median of $32.1 million in 2023.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Total Liabilities fell by 11.26% in 2022, and later surged by 55.26% in 2024.
  • 4D Molecular Therapeutics' Total Liabilities (Yearly) stood at $31.9 million in 2020, then climbed by 7.63% to $34.4 million in 2021, then declined by 11.26% to $30.5 million in 2022, then rose by 5.09% to $32.1 million in 2023, then skyrocketed by 55.26% to $49.8 million in 2024.